Dexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.

Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus ...

JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

A new bill in Arkansas is the first on a state level to try and stem the “migration” of coverage for continuous glucose monitors to a pharmacy-only benefit.

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that focuses on the design, development, and ...

Dexcom reported Q4 results, with revenue up 8%, beating estimates. CEO looks forward to unlocking next wave of global access.

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

DexCom Inc (DXCM) reports strong international growth and expanding customer base, while facing margin pressures and US ...